RFK Jr. Proposal on Unproven Peptides Draws FDA Scientist Pushback
A reported proposal by Health Secretary Robert F. Kennedy Jr. to have the FDA overlook unproven peptide products has drawn sharp criticism from agency scientists, according to reporting by Ars Technica.
Peptides—short chains of amino acids used in supplements and some therapeutic applications—have grown in popularity, but FDA scientists have stated that none of the widely available peptide products have been proven safe or effective for their marketed uses. The proposed policy would reportedly allow such products to remain available without regulatory action.
Critics within the agency argue that such an approach would undermine the FDA's core function of protecting public health by ensuring medical products meet evidentiary standards. The agency historically requires scientific evidence demonstrating both safety and efficacy before products can be marketed for therapeutic purposes.
The debate highlights ongoing tensions between regulatory flexibility and evidence-based oversight in the supplement and peptide markets, where products often reach consumers before completing formal clinical evaluation.